News

Media Releases                  Media Archives                  In The Media

2010/2011 MILESTONES:

 

• US Patent Office reverses previous objections to Benitec’s foundational Graham patent (October 2010), effectively clearing the way for patent to be re-issued in the US (February 2011).

• Results published of pilot Phase I/II clinical study in HIV/AIDS-related lymphoma showing safety and feasibility (June 2010). 

• Benitec extends its in-house pipeline: In addition to its previously announced pipeline of proof of concept programs in hepatitis B (commenced September 2009 and extended in February 2011), drug-resistant lung cancer (November 2009) Benitec announced the commencement of a key program to turn off chronic cancer-associated pain in October 2010.

• Benitec renegotiates technology licensing agreement on more favorable commercial terms (January 2010) and obtains $6 million funding commitment from US investor (April 2010).

• Benitec appoints new CEO and restructures the Board (June 2010), and forms a Chief Investigators Group comprising international researchers who are collaborating on Benitec’s internal R&D programs (February 2011).

 

BOARDROOM RADIO INTERVIEW WITH PETER FRENCH

Benitec Limited provides the opportunity to listen to an audio broadcast with Dr Peter French discussing "Benitec patent outcomes underpin capital raising and company outlook". To hear the discussion, please follow this link: Boardroom Radio

 

ACCESS BENITEC's ASX & MEDIA RELEASES:

• released during 2010 and 2011
• archived - released from 2002 to 2009

 

BENITEC IN THE MEDIA

Cancer Gene Therapy | March 2011

Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs

Science Translational Medicine | 17 June 2010

RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma

Cancer Research | 15 June 2010

βIII-Tubulin Is a Multifunctional Protein Involved in Drug Sensitivity and Tumorigenesis in Non–Small Cell Lung Cancer

Interview with Sue MacLeman, CEO on Boardroom Radio | 8 February 2010

Nature Biotechnology | January 2010

The intellectual property landscape for gene suppression technologies in plants

NSi Collaboration with Benitec to Develop an RNAi Therapeutic for Lung Cancer | November 2009

Nature Journal | January 22, 2009

The promises and pitfalls of RNA-interference-based therapeutics

Intersuisse Report London Forum | October, 2007

Intersuisse Investment Research | August 1, 2007

DNA-directed RNAi and the crown jewels

Australian Life Scientist, April 1, 2007

Benitec Featured in the Australian | November 11, 2006

Benitec hopes big Merck deal will silence critics | The Age, November 6, 2006

In the Range | The Daily Telegraph, November 1, 2006

Benitec Featured on ABC TV's Catalyst | April 20, 2006
Link

Health Journal Television Interview
WMV Video Feed

Chemistry & Industry | February 21, 2005
Running Interference (pdf 3.5MB)

BioIT World | February 18, 2005
RNAi Therapeutics (pdf 185k)

VentureWire Alert | October 7, 2004
Venture Market Summary: RNAi Overview (pdf 41k)

Daily Telegraph | September 23, 2004
In Human Eyes, Hope of Taming Bad Genes (pdf 207k)

New York Times | September 14, 2004
Method to Turn Off Bad Genes Is Set for Tests on Human Eyes (pdf 156k)

Wired | August 13, 2004
Building Blocks for a Tiny World
Ribonucleic acid, or RNA, is no longer just a slave to DNA's commands.
It may be the strongest building material yet for making nanostructures.

Drug Discovery & Development | August, 2004
The Sound of RNAi Silencing (pdf 919k)

• more news articles